Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Bolt Biotherapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 40 | 35 | −5 |
| Shares | 25.1M | 24.5M | −523.9K (−2.1%) |
| Value | $32.1M | $25.5M | −$6.56M (−20.4%) |
New holders (3)
Institutions that held Bolt Biotherapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 86 | $89 | 0.00% |
| Qube Research & Technologies Ltd | 2 | $2 | 0.00% |
| Royal Bank of Canada | 94 | $0 | 0.00% |
Sold out (8)
Institutions that held Bolt Biotherapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Goldman Sachs Group Inc | 284,170 | $363.7K |
| Assenagon Asset Management S.A. | 158,289 | $202.6K |
| Prudential Financial Inc | 24,400 | $31.2K |
| XTX Topco Ltd | 13,309 | $17.0K |
| Bank of New York Mellon Corp | 12,578 | $16.1K |
| Stifel Financial Corp | 12,264 | $15.7K |
| Tower Research Capital LLC (TRC) | 652 | $835 |
| Northwestern Mutual Wealth Management Co | 400 | $512 |